JPMorgan lowered the firm’s price target on Grifols (GRFS) to $10 from $10.30 and keeps a Neutral rating on the shares. The firm adjusted ratings and targets in the European pharma group as part of its 2026 outlook. It expects sector performance to be driven by pipeline readouts, saying much of the concern around the impact of U.S. price pressure on sector earnings has dissipated in Q4. JPMorgan downgraded companies with a lack of pipeline readouts in 2026.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GRFS:
- Grifols SA Reports Strong Q3 Earnings Amid Challenges
- Grifols SA Reports Strong Q3 2025 Financial Results
- Grifols Reports Strong Q3 2025 Financial Performance with Biopharma Growth
- Grifols reports Q3 adjusted EBITDA of EUR 482M, up 8.8% in constant currency
- GRFS Earnings Report this Week: Is It a Buy, Ahead of Earnings?